Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with lung cancer, liver cancer and other solid cancers
Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents
At least one measurable lesion
Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function
You may not be if
patients treated with PD-1 agents less than 2 terms
